We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current ACOR market cap is 15.27M. The company's latest EPS is USD -53.0683 and P/E is -0.22.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 38.09M | 33.32M | 22.26M | 29.68M | 34.83M |
Operating Income | -4.99M | -6.39M | -12.57M | -4.46M | -604k |
Net Income | -13.85M | 19.14M | -16.82M | -9.38M | -8.89M |
Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 471.43M | 279.34M | 183.86M | 129.07M | 131.12M |
Operating Income | 38.49M | -311.63M | -60.14M | -77.31M | -42.04M |
Net Income | 33.68M | -272.97M | -99.59M | -103.95M | -65.92M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 393.34M | 395.6M | 374.91M | 364.7M | 366.34M |
Total Liabilities | 317.57M | 301.97M | 297.95M | 296.83M | 307.39M |
Total Equity | 75.77M | 93.62M | 76.96M | 67.87M | 58.96M |
Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 1.3B | 799.72M | 632.68M | 455.47M | 395.6M |
Total Liabilities | 687.68M | 488.9M | 394.73M | 304.33M | 301.97M |
Total Equity | 611.98M | 310.82M | 237.96M | 151.14M | 93.62M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -29.99M | -20.92M | -7.02M | -18.57M | -10.97M |
Investing | -260k | -136k | N/A | N/A | -220k |
Financing | N/A | N/A | N/A | N/A | N/A |
Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 150.79M | -128.17M | -61.01M | -41.35M | -20.92M |
Investing | -176.87M | -505k | 59.36M | 73.78M | -136k |
Financing | 12.8M | -60.55M | -1.67M | -69.66M | N/A |
Market Cap | 15.27M |
Price to Earnings Ratio | -0.22 |
Price to Sales Ratio | 0.11 |
Price to Cash Ratio | 0.39 |
Price to Book Ratio | 0.16 |
Dividend Yield | - |
Shares Outstanding | 1.24M |
Average Volume (1 week) | 3.11k |
Average Volume (1 Month) | 4.53k |
52 Week Change | 13.61% |
52 Week High | 24.196 |
52 Week Low | 8.978 |
Spread (Intraday) | 0.61 (4.92%) |
Company Name | Acorda Therapeutics Inc |
Address |
1209 orange st wilmington, delaware 19801 |
Website | https://www.acorda.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions